Ammonio Methacrylate Copolymer (Type B)-Diltiazem Interactions in Solid Dispersions and Microsponge Drug-Delivery Systems

Iliyan Kolev 1,*, Nadezhda Ivanova 2,*, Tanya Topouzova-Hristova 3, Tanya Dimova 1, Pavlina Koseva 1, Ivalina Vasileva 1, Sonya Ivanova 1, Anton Apostolov 4, Gergana Alexieva 5, Atanas Tzonev 6 and Vesselin Strashilov 6

Abstract: This paper presents a complex analytical study on the distribution, solubility, amorphization, and compatibility of diltiazem within the composition of Eudragit RS 100-based particles of microsponge type. For this purpose, a methodology combining attenuated total reflectance Fourier transform infrared (ATR-FTIR) absorption spectroscopy, differential scanning calorimetry (DSC), scanning electron microscopy with energy-dispersive X-ray microanalysis (SEM-EDX), and in vitro dissolution study is proposed. The correct interpretation of the FTIR and drug-dissolution results was guaranteed by the implementation of two contrasting reference models: physical drug–polymer mixtures and casting-obtained, molecularly dispersed drug–polymer composites (solid dispersions). The spectral behavior of the drug–polymer composites in the carbonyl frequency ($\nu_{\text{CO}}$) region was used as a quality marker for the degree of their interaction/mutual solubility. A spectral-pattern similarity between the microsponge particles and the solid dispersions indicated the molecular-type dispersion of the former. The comparative drug-desorption study and the qualitative observations over the DSC and SEM-EDX results confirmed the successful synthesis of a homogeneous coamorphous microsponge-type formulation with excellent drug-loading capacity and "controlled" dissolution profile. Among them, the drug-delivery particles with 25% diltiazem content (M-25) were recognized as the most promising, with the highest population of drug molecules in the polymer bulk and the most suitable desorption profile. Furthermore, an economical and effective analytical algorithm was developed for the comprehensive physicochemical characterization of complex delivery systems of this kind.

Keywords: diltiazem; Eudragit RS; microsponge drug delivery; solid dispersions

1. Introduction

Acrylate and methacrylate polymers are widely used in the pharmaceutical industry as matrix- or film-forming materials [1,2]. The development of solid amorphous drug–polymer...
dispersions is the most common goal when subjecting them to the various techniques of molding/casting, hot-melt extrusion, 3D printing, solvent evaporation, granulation, precipitation, etc. [3–5]. Compared to the solid crystalline dispersions, the solid amorphous drug–polymer dispersions are characterized by increased homogeneity, permeability, drug saturation point, and drug release [2]. Not by accident, the predominantly amorphous-in-nature ammonio methacrylate copolymers (Eudragit® RS and RL), butylated methacrylate copolymer (Eudragit® E), and methacrylic acid–methyl methacrylate copolymer 1:1 (Eudragit® L) [6] are applied as crystallization inhibitors (both on nucleation and crystal growth) in the composition of miscellaneous drug-delivery carriers [7–9]. The polymers’ amorphization potency depends on the processing methods and variables and the drug properties; they determine critical qualities of the final product, such as matrix/membrane permeability, porosity, stability, solubility, desorption pattern, etc. [7,10].

Ammonio methacrylate copolymer type B (Eudragit® RS) is a polycationic polymer composed of methyl methacrylate and ethyl acrylate units, among which 4.5 to 7.0% methacrylic acid esters with quaternary ammonium groups are to be found [6]. The latter determine the permeability of the polymer, which indeed possesses a water-insoluble structure and pH-independent swelling [2,11,12]. Eudragit® RS finds a broad application in the development of sustained-release drug-dosage forms and drug-delivery systems; it displays thermoplasticity and considerable chemical stability, wherefore is considered suitable for pharmaceutical processing [2].

In our previous works we presented the synthesis and physicochemical, functional, and biopharmaceutical characterization of diltiazem-loaded Eudragit RS microsponges [13,14]—a highly preferable drug-carrier system in solid as well as in semisolid dosage forms [15,16]. The microsponges were designated to serve as a controlled delivery system in diltiazem 2% rectal hydrogels. The method used for their preparation (quasi-emulsion solvent diffusion method) belongs to the precipitation- and solvent-evaporation techniques [17]. To further extend the structural knowledge of the particles obtained, we herein suggest complex FTIR and sorption studies on the microporous matrix-typed microsponges along with two control (reference) models: physical drug–polymer mixtures and homogeneous solid drug–polymer dispersions, obtained by a casting approach (Figure 1). The morphological, elemental, and functional peculiarities of the drug-delivery system in question are additionally investigated by applying SEM-EDX and DSC.

Figure 1. Schematic illustration of diltiazem and Eudragit RS and the expected structural assignment of their composites obtained by different techniques.

2. Materials and Methods

2.1. Materials

Diltiazem hydrochloride 99.9% was purchased from Puho Pharmaceuticals Co. Limited, Guangzhou, China. Ammonio methacrylate copolymer (type B) (Eudragit® RS 100) was a kind gift from Evonik Industries AG (Darmstadt, Germany). Poly(vinyl alcohol), Mw
49.000 Da was purchased from Sigma Aldrich, St. Louis, MO, USA. Dialysis membranes were provided from a local hospital (10 kDa molecular weight cutoff). The solvents ethanol (anhydrous) and dichloromethane (DCM, HPLC grade > 97.8%) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.2. Methods

2.2.1. Sample Preparation

Three working models of diltiazem-Eudragit RS mixtures were prepared, each at a minimum of three concentrations: 5%, 15%, and 25% diltiazem content. Additionally, the reference formulations (explained below) were also prepared at 10% and 20% diltiazem content.

Model I (subject of the study): Diltiazem-loaded Eudragit RS microsponges (M) were prepared by a quasi-emulsion solvent-diffusion method. In short, a molecular solution of diltiazem base and polymer Eudragit RS (in varying ratios; Table 1) in dichloromethane was droplet-wise added to an external aqueous phase, containing poly (vinyl alcohol) as surfactant. The resultant mixture was kept under continuous stirring until sufficient hardening of the particles and vaporization of the organic solvent. The particles were isolated by filtration and purified by multiple washing. A microsponge-type morphology was established (polymeric, microsized, highly porous spheres). The exact protocol for the synthesis is described elsewhere [13,14].

Table 1. Mass ratios of diltiazem and the polymer Eudragit RS 100.

| Code | Used Amounts of Diltiazem and Eudragit RS, W/W% |
|------|-----------------------------------------------|
| P-5  | 5/95                                          |
| P-10 | 10/90                                         |
| P-15 | 15/85                                         |
| P-20 | 20/80                                         |
| P-25 | 25/75                                         |
| C-5  | 5/95                                          |
| C-10 | 10/90                                         |
| C-15 | 15/85                                         |
| C-20 | 20/80                                         |
| C-25 | 25/75                                         |
| M-5  | 5/95                                          |
| M-15 | 15/85                                         |
| M-25 | 25/75                                         |

Model II (control model): Physical mixtures of diltiazem and Eudragit RS (P) were obtained by manually grinding predetermined amounts of diltiazem and Eudragit RS (Table 1) at room temperature (21 °C) for approximately 10 minutes. For the homogenization, an agate mortar and a pestle were used.

Model III (control model): Highly-dispersed diltiazem-Eudragit RS composites (solid solutions) (C) were obtained by dissolving 15.0 mg of diltiazem and precisely determined amounts of Eudragit RS in 5.0 mL dichloromethane-solvent, appropriate for both components. Each solution was cast into a clock glass and evaporated to dryness in a well-ventilated hood. The C-samples presented as thin, homogeneous, semitransparent films. When needed, samples for analysis from the C-series were extracted by scraping with a metal spatula.

2.2.2. ATR-FTIR Spectroscopy

The attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectra were recorded on a Tensor II FTIR spectrophotometer (Bruker, Germany) in the attenuated total reflection (ATR) mode, at a resolution of 0.4 cm⁻¹ accumulating 32 scans. The spectra were collected at room temperature. The OPUS 8.0 software was used to autocorrect the spectral baselines.
2.2.3. In Vitro Dissolution Test

Drug-dissolution studies were performed on EU pharmacopoeial dissolution apparatus type II (Dissolution Tester Model PT-DT 70, Pharmatest, Germany). Each analyte was weighed in an amount equivalent to 15.0 mg of diltiazem. P and M samples were suspended in 1.0 mL of distilled water and placed in cellulose acetate dialysis bags with a molecular cutoff of 10 kDa. The pouches thus formed were attached to the paddles of the dissolution tester using cotton threads. The C- specimens (together with the clock-glasses) were placed at the bottom of the dissolution vessel. As a dissolution medium, distilled water at a volume of 400 mL was used. All samples were allowed to swell freely for 24 h under static conditions prior to starting their dissolution testing. At the end of this stage, the losses of the target analyte (diltiazem) in the dissolution media during the swelling process were analyzed.

In order to initialize dissolution and diffusion-controlled drug release of diltiazem in the aqueous media, equimolar (to the applied drug) amounts of hydrochloric acid (concentrated) were added to each vessel. The dissolution tester was set at 25 ± 0.5 °C and a rotation speed of 30 rpm. The concentration of diltiazem hydrochloride was assessed at even time intervals for 9.0 h. After each sampling, fresh aliquots of the dissolution medium (1.0 mL) were added. Quantification was performed using an optimized and validated UV-Vis spectral method, described in previous work of ours [14].

2.2.4. DSC

Differential scanning calorimetry tests were performed on microsponge (M-25) samples and the raw materials (diltiazem and Eudragit RS 100) by using DSC Q200 (TA Instruments, New Castle, DE, USA). Samples (~6–7 mg) were run in two modes: (1) heating-only mode from 0 to 250 °C at 10 °C/min heating rate and (2) heating–cooling–heating mode in the temperature interval from 0 to 250 °C at 10 °C/min. All DSC runs were performed under nitrogen flow (50 mL/min).

2.2.5. Scanning Electron Microscope Images and EDX-Analysis

The air-dried samples (M-25 particles) were embedded in paraffin without additional dehydration steps to avoid dissolving the lipophilic components. The resulting blocks were cut into semithin sections (20 micrometers) using a conventional histological microtome (Microtome 1508A, Nanjing Oxy Technology and Trading Co., Ltd., Shanghai, China) and mounted on a graphite base for observation. The size and morphology of the polymeric particles (viz. M-25 sample) as well as the elemental analysis of the so-obtained microtome cuts were studied by scanning electron microscope (SEM, Tescan LYRA I XMU dual beam SEM/FIB system), equipped with an energy-dispersive X-ray analyzer (Bruker EDX detector Quantax 200).

3. Results and Discussion

Diltiazem was introduced in Eudragit RS matrices by different approaches in order to follow the changes in the polymers’ amorphization potency, permeability, solubilization capacity for diltiazem, and desorption behavior. The focus of the study was directed to the newly synthesized diltiazem-loaded Eudragit RS microsponges, herein marked as M-samples. Two other models were proposed as control formulations for the interpretation of the obtained results (Figure 1). The first control (reference) model, P-series, was designed to represent a heterogeneous drug–polymer dispersion, in which the drug molecules are primarily distributed on the polymeric particles’ surface. The second control model, C-series, on the contrary, aimed to achieve a maximum level of homogeneity and dispersivity between the two components; within this model, the drug is expected to be molecularly dissolved in the polymeric matrix, whereas only molecules in excess will show the tendency to crystallize on the polymeric surface.
3.1. ATR-FTIR Analysis

The complete vibrational-frequency assignments of diltiazem (base) are presented in Figure 2. Most assignments were made by comparing the spectrum of the diltiazem as obtained by us with that of its hydrochloric salt [18].

![Figure 2. Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectrum of diltiazem base.](image)

**Carbonyl Group Vibrations**

- **Qualitative observations**

  In the progress of our observations, we found out that the proposed ATR-FTIR method acquires satisfactory performance (with the required high analytical sensitivity and specificity) in a relatively narrow wavenumber range of about $50 \text{ cm}^{-1}$ (from 1700 to 1650 $\text{ cm}^{-1}$) (Figure 3). Similarly, in many other circumstances, it has been assumed relevant to track out the changes in the carbonyl frequency ($\nu_{\text{CO}}$) region when carbonyl-bearing drug molecules are examined [19–21].

![Figure 3. A sensitive region in the infrared spectra of diltiazem, Eudragit RS, and their control formulations—physical mixtures (P) and solid dispersions (C)—at 25% drug concentration (samples P-25 and C-25).](image)
Diltiazem shows two highly characteristic, well-defined, and readily recognizable C=O stretching bands with relatively high intensity in the range of 1760–1660 cm\(^{-1}\) (Figures 2 and 3). The band observed at 1746 cm\(^{-1}\) is assigned to the CO group of the acetate functional, and that positioned at lower frequencies (with a maximum at 1673 cm\(^{-1}\)) is assigned to the CO functional group of the seven-membered lactam ring [22]. In the same spectral interval, however, the presence of a very intense and broad IR band (with a max. at 1723 cm\(^{-1}\)) in the spectrum of the polymer Eudragit RS 100 was also registered (Figure 3). Certainly, this last-mentioned absorption band should be considered as consisting of at least three overlapping bands corresponding to the three different kinds of grafted carbonyl (ester) groups on the polymeric backbone (Figure 1). According to the generally accepted theory of infrared spectroscopy, however, when solvent–solute mixtures of two or more constituents are examined (as in the case here studied), considerable frequency shifts of all carbonyl groups due to mutual interference effects are expected to appear. Usually, the used solvent (a liquid of low-molecular-weight organic substance) or a high-molecular organic matrix (polymer) affects both the position and the intensity of each absorption band of the examined solute (diltiazem) via the so-called solvent effect. Indeed, when the spectra of diltiazem–Eudragit RS physical mixtures (P) and solid solutions (C) were analyzed, considerable differences in the CO frequency pattern of each participant from its native spectrum were registered (Figure 3).

Concerning the lower-frequency subzone, from 1690 to 1660 cm\(^{-1}\) (Figure 3), the appearance of a new absorption band at 1684 cm\(^{-1}\) in the spectra of both types of mixtures (P and C models) was recorded. In the case of the physical mixtures, the presence of this band (normally detected as a shoulder on the high-energy tail of the primary band at 1673 cm\(^{-1}\)) was, as a whole, less pronounced. In the spectra of the solid solutions (C), however, this band occurs as spectrally predominant and thus indicative of the successful dispersing of drug molecules in the polymer matrix. It is reasonable to assume that the emerging new band increases its intensity as a function of the extent of mixing (dispersing) the drug molecules into the polymeric bulk, whereas the lower one, at 1673 cm\(^{-1}\), accordingly decreases its integral transparency. The shift in the observed CO frequency of about 11 cm\(^{-1}\) should, in principle, be attributed to the effect of strong dipole–dipole interaction between molecules of the used solvent, Eudragit RS 100, and the dispersed solute, diltiazem.

- Quantitative observations

All types of diltiazem–Eudragit RS mixtures were studied at varying concentrations in order to determine the point of saturation for each of the techniques applied and follow other concentration-dependent changes within the polymer matrix (Figure 4).

![Figure 4](image-url) Concentration-dependent changes in the infrared spectra of (A) physical diltiazem-Eudragit RS mixtures (P) and (B) solid diltiazem–Eudragit RS solutions (highly dispersed composites) (C).

The appearance of a C=O stretching vibration band at 1684 cm\(^{-1}\) (as a “shoulder” to the intrinsic 1673 cm\(^{-1}\) band) in the spectra of all diltiazem–Eudragit RS 100 physical
mixtures (P) should be directly ascribed to the particularities of the preparation technique. Upon mixing of the two constituents, due to significant variations in their hardness and the relatively high coefficient of applied friction, an effect of partial mutual diffusion (penetration) between both ground constituents is expected to occur at the points of contact. Thus, the “distinct” neighboring molecules diffuse, creating a heterogeneous composite mixture of microparticles consisting of a polymeric core and an outer “functionalized” shell of irregularly organized diltiazem molecules. As the drug content increases, however, the population of diltiazem molecules included in the polymeric volume reaches its limit (the point of saturation), while the molecules in excess form an intact diltiazem phase; the latter displays the characteristic for the drug IR absorption behavior (i.e., abs. maximum at 1673 cm\(^{-1}\)). Approaching the drug-saturation point of the polymeric surface, no further increase in the intensity of the 1684 cm\(^{-1}\) band is observed, whereas the 1673 cm\(^{-1}\) band continues to “grow”. A deconvolution analysis in the C=O (lactamic) stretching vibrations range (from 1700 to 1650 cm\(^{-1}\)), performed with the aid of specialized peak-fitting software, Origin 8.1 (Tables A1–A10, Appendix A), allowed us to define the exact point of polymer saturation with diltiazem when the drug is introduced via mechanical grinding and mixing (P models) (Figure 5).

![Figure 5](image_url)

**Figure 5.** Deconvolution analysis in the C=O (lactamic) stretching vibrations range for physical drug–polymer mixtures (P models); (A) an example for deconvolution analysis carried on Sample P-25 spectrum (the same analysis is carried for all other samples-Tables A1–A10, Appendix A) and (B) determination of drug-saturation point of the polymer matrix by the physical-mixing approach; the curve in red presents optimized processing of the deconvolution analysis data, in which the cause for the low regression coefficient (R\(^2\))–a peak at 1653 cm\(^{-1}\), is not taken into account.

Concerning the spectra of diltiazem–Eudragit RS solid solutions (C models), significant changes in the considered wavenumber range were registered. The appearance of several new bands was observed for all concentrations examined (Figures 4B and 6). Each of the newly appearing bands may be assigned to a complex intermolecular interaction between the two constituents, diltiazem and Eudragit RS. The good mutual solubility between them was illustrated and confirmed by the appearance of three new bands in the C=O stretching region (at 1663, 1670/1671, and 1684 cm\(^{-1}\)) and by the reduction in the intensity of the absorption band at 1673 cm\(^{-1}\). Nonetheless, the spectral patterns of the highly dispersed mixtures (C probes) were considered too complex for a clear identification to be made. Still, it is reasonable to assume that during the process of homogeneous dispersion, the drug molecules occupy regions of the polymeric matrix with different degree of crystallinity, and to a certain extent dielectricity, which produce detectable frequency variations in νCO of the drug solute.
Polymers 2022, 14, 2125 8 of 16

Concerning the spectra of diltiazem–Eudragit RS solid solutions (C models), the sorption behavior of the microsponge samples (M) showed an intermediate interaction between the two constituents, diltiazem and Eudragit RS. The good mutual solubility between them was illustrated and confirmed by the appearance of three new interaction bands in the C=O stretching region (at 1663, 1670/1671, and 1684 cm$^{-1}$). Each of the newly appearing bands may be assigned to a complex intermolecular interaction between the two constituents. The polyme ric matrix possesses a higher capacity for more organized polymeric matrix. As solid solutions are formed, the drug excess, drug/polymer amorphization and entraps diltiazem in a much denser, less permeable, desorption. Based on the FTIR results and the visual appearance of these samples, the spectral profile of the solid drug–polymer solutions (C samples) (Figure 7). This observation does not correspond to the fact that—as shown in Figure 7—the population of dispersed diltiazem molecules (absorbing at 1673 cm$^{-1}$) in the bulk of the two kinds of materials is different. Comparing the respective peak heights of the relevant bands in the spectrum of the M-25 sample, one could see that the proportion of occluded to easily diffusing (absorbing at 1673 cm$^{-1}$) diltiazem molecules appears to be significantly lower than that of its C-25 equivalent. As it will be shown below, these observations have led us to an adequate explanation of the unusual desorption behavior of the sample in question at neutral pH. However, such a result testifies for good homogeneity and amorphization of diltiazem within the microsponge-type polymeric matrix.

Figure 6. An example of deconvolution analysis carried out on Sample C-25 spectrum.

Figure 7. Spectral similarity between the infrared spectra of drug-loaded microsponges (M) and drug–polymer solid dispersions (C).

3.2. Dissolution Rate Study

All diltiazem–Eudragit RS models were subjected to drug dissolution (desorption) studies in order to relate their structural features to some important functional properties: apparent solubility, drug diffusivity, and matrix permeability. To identify the potential resultant differences as a function of the diffusion-controlled drug release in particular, all samples were allowed to swell before initializing the drug dissolution. The period of swelling (24 h) slightly affected the drug load in the matrices since diltiazem base is a
strictly hydrophobic molecule [13]. Only when a concentrated solution of hydrochloric acid was applied in a stoichiometrically calculated volume ratio (after the “swelling” stage) was the drug base allowed to form its highly water-soluble salt (453 mg/mL in distilled water at 37 °C [13]) and diffuse into the aqueous media (Figure 8).

Figure 8. Diltiazem release from physical mixtures (P), solid dispersions (C), and microspone (M) formulations.

The physical drug–polymer mixtures (P) showed the fastest and most complete drug-release rate among all models. This result supports the data from the FTIR analysis, which indicated a low degree of interaction between the components upon their mixing by mechanical grinding. As the drug is only superficially located onto the polymeric particles, there are not expected to be any particular barriers to its diffusion, except its intrinsic solubility. Moreover, as the relative drug content in the P-models increases, the dissolution rate decreases. Eudragit RS may be here reviewed as a “solid” mediator for the drug particles’ size reduction; therefore, the higher the polymeric content in these mixtures, the larger the active surface area of diltiazem and the faster the dissolution.

The casting-obtained C-probes demonstrated minimal and incomplete drug desorption. Based on the FTIR results and the visual appearance of these samples (semitransparent films), it could be claimed that this model provides less potency for drug/polymer amorphization and entraps diltiazem in a much denser, less permeable, and more organized polymeric matrix. As solid solutions are formed, the drug excess, however, showed the tendency to crystalize on the polymeric surface. Accordingly, the higher the relative drug content, the higher the excess and the released drug portion.

The sorption behavior of the microspone samples (M) showed an intermediate position compared to the two reference models (P and C). However, a resemblance was observed with the C formulations. The polymeric matrix possesses a higher capacity for diltiazem incorporation and greater permeability when a porous structure is obtained (as in the case of the drug-loaded microsponges [13]). In this regard, the M samples, although proven to be as highly dispersed as the C samples, ensure faster and more complete drug release after matrix swelling. The more significant the polymeric contribution within the microspone particles, the longer the diffusion path for diltiazem; hence, samples with higher relative drug content and respective lower polymeric content showed superiority with respect to drug release.

3.3. DSC Analysis

Figure 9A shows the thermograms obtained via the heating-only mode for diltiazem (base), diltiazem hydrochloride, Eudragit RS 100, and M-25 sample. Diltiazem base was demonstrated to melt at 103.8 °C, which is in agreement with the literature data (105–107 °C) [23]. From the same figure, we detected a melting point at 214.5 °C for the
hydrochloride salt, which again corresponds well to the literature [23]. The melting of diltiazem hydrochloride (~225 °C) is accompanied by decomposition, which becomes apparent above 230 °C [18]. Two peaks, at 63.1 and 183.6 °C, appear in the thermogram of the pure Eudragit RS 100 polymer. The first is the glass transition, which is reported to occur between 61.9 and 64.9 °C [24]. The high temperature peak (183.6 °C) is due to Eudragit RS 100 melting, which is known to occur at ~187 °C [25].

In the thermogram of the M-25 sample, the melting peak of diltiazem disappears. This result confirms that the drug is in the amorphous state and that the formulation is, in fact, a molecular dispersion of diltiazem inside the polymer [26]. Similar findings are characteristic of highly dispersed systems (solid solutions) obtained via hot-melt extrusion, for example [25,27]. The interaction between the drug and the polymer results in the amorphization of both constituents within the M-25 formulation, hence the lack of their respective melting peaks. Another observation that could be seen is the appearance of a new peak at a temperature just above 200 °C. A possible explanation is the in situ formation of diltiazem hydrochloride salt (melting point at ~225 °C), as diltiazem base in the particles is prone to react with the polymeric [Cl−] counterions (Figure 1). Such ion-exchange reactions are reported for Eudragit RS upon melting [28]. Another reasonable explanation could be the degradation of diltiazem (detected for the pure drug above 230 °C) at a lower temperature due to its amorphization and molecular dispersivity in the polymer matrix. The decrease in the polymer’s glass transition in the M-25 composition by 13 °C (as compared to that of the pure Eudragit RS) is likely due to the formation of a looser polymer network and increased free volume in the presence of diltiazem [29].

The heating–cooling–heating mode results (Figure 9B,C) confirm the abovementioned observations. After cooling and second heating, the glass transition of Eudragit RS (63.1 °C) manifests without the relaxation enthalpy peak, and a kink typical for an irreversible process appears.

3.4. SEM-EDX Analysis

SEM-EDX technique was applied to identify the elemental composition along a cut made on paraffin-embedded particles from the M-25 formulation. The primary morphological characteristics are shown in Figure 10A. On the micrograph obtained, we distinguished and marked three zones, namely (1) clear cuts/slices of microsponge particles (#1 and #2); (2) intact microsponge particles (#3, #4, and #5); and (3) paraffin base (surrounding the visible particles). The white arrow on Figure 10B shows exactly where an EDX scan analysis was performed. In the same figure, the dynamics of the elemental composition (for S, N, O, and Cl) along the cut can be followed.

![Figure 9. (A) Thermograms of diltiazem base, diltiazem hydrochloride, Eudragit RS 100, and M-25 sample in heating-only mode; (B) thermogram in the heating–cooling–heating mode of Eudragit RS 100; (C) thermogram in the heating–cooling–heating mode of M-25 sample.](image-url)
Our attention was directed to the sulfur (S), which indicates the distribution of diltiazem (S-containing drug) in the polymeric matrix-type particles. As no specific cumulation patterns were recognized on the scan, we should conclude that the drug possesses a relatively even distribution in the polymeric volume. The observed fluctuation in the S content, as well as in the other elements’ content, could be attributed to the architectural peculiarities of this type of microsponge materials, consisting of randomly alternating zones of hollow micropores (in which the X-ray emission is reduced) and solid walls.

4. Conclusions

Combining some of the benefits of infrared spectrophotometry, differential scanning calorimetry, energy-dispersive X-ray microanalysis, and dissolution testing, we proposed a methodological algorithm by which we were able to analyze the molecular distribution of diltiazem in the bulk of Eudragit RS 100-based particles of microspongeous type. For the purposes of the analysis, we proved the ability to accurately relate the spectral and desorption behavior of our drug-delivery systems to analogous reference formulations—physical mixtures and highly dispersed composites (solid dispersions). Based on the methodology set out, we were able to establish that the sample preparation technique for this type of drug carriers results in an even, homogeneous, and molecular-type drug distribution within the polymer matrix. Despite the spectral similarity with the solid drug-polymer solutions, the drug-delivery particles presented a substantially increased drug-dissolution rate owing to their porosity. For the sake of comparison, the microsponge model was proved to combine the benefits of both reference models, namely molecular distribution in the polymeric bulk (needed to exert control over the drug release) and satisfactory drug-solubility rate. The result is considered highly valuable for the development of controlled-release drug-delivery systems. In addition, this work presents an economical and rapid algorithm for the correct analysis of drug carriers of this type.

Author Contributions: Conceptualization, I.K. and N.I.; methodology, I.K. and N.I.; software, I.K., N.I. and A.A.; investigation, I.K, N.I., T.T.-H., S.I., P.K., I.V., T.D., A.A., A.T., G.A. and V.S.; data curation, I.K., N.I., A.A., G.A. and V.S.; writing—original draft preparation, I.K., N.I., A.A. and V.S.; writing—review and editing, I.K. and N.I.; visualization, I.K, N.I., S.I., P.K., I.V., T.D. and G.A.; supervision, I.K., N.I., A.A., G.A. and V.S.; project administration, I.K. and N.I.; formal analysis, I.K., N.I., A.A., G.A. and V.S.; resources, I.K, N.I., T.T.-H., S.I., P.K., I.V., T.D., A.A. and A.T.; validation, I.K. and N.I. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by the Medical University Varna.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.
Appendix A

Spectral deconvolution is an algorithm-based curve-fitting process used to find the best collection of overlapped peaks; whose sum closely matches their composite (original) spectrum.

The integral areas of individual peaks were determined using the curve-fitting application of Origin 8.1 software. All spectra were deconvoluted in the range of C=O (lactamic) stretching vibrations (from 1700 to 1650 cm$^{-1}$). To obtain reliable results, a rational choice of several parameters was also applied. Validation tests based on analysis of variance (ANOVA) were also accomplished. The results of the analyses are given in the following tables:

Table A1. Sample P-5.

| STATISTICS          | ANOVA          |
|---------------------|----------------|
| Number of points    |                |
| Degrees of freedom  | 36 Regression  |
|                     | 6 Residual     |
| Reduced Chi-square  | 30 B           |
| Adj. R-square       | 9.5725 $\times$ 10$^{-7}$ |
| Fit status          | Succeeded      |

Table A2. Sample P-10.

| STATISTICS          | ANOVA          |
|---------------------|----------------|
| Number of points    |                |
| Degrees of freedom  | 36 Regression  |
|                     | 6 Residual     |
| Reduced Chi-square  | 30 B           |
| Adj. R-square       | 1.778 $\times$ 10$^{-4}$ |
| Fit status          | Succeeded      |

Table A3. Sample P-15.

| STATISTICS          | ANOVA          |
|---------------------|----------------|
| Number of points    |                |
| Degrees of freedom  | 36 Regression  |
|                     | 6 Residual     |
| Reduced Chi-square  | 30 B           |
| Adj. R-square       | 2.54281 $\times$ 10$^{-6}$ |
| Fit status          | Succeeded      |
Table A4. Sample P-20.

| STATISTICS          | ANOVA               |
|---------------------|---------------------|
| Number of points    | 36                  |
| Degrees of freedom  | 30                  |
| Reduced Chi-square  | 4.256               |
| Adj. R-square       | 0.9906              |
| Fit status          | Succeeded (100)     |

| Number of points    | B                   |
| Degrees of freedom  | B                   |
| Reduced Chi-square  | B                   |
| Adj. R-square       | B                   |
| Fit status          | B                   |

Table A5. Sample P-25.

| STATISTICS          | ANOVA               |
|---------------------|---------------------|
| Number of points    | 36                  |
| Degrees of freedom  | 30                  |
| Reduced Chi-square  | 6.99189 × 10⁻⁶      |
| Adj. R-square       | 0.9882              |
| Fit status          | Succeeded (100)     |

| Number of points    | B                   |
| Degrees of freedom  | B                   |
| Reduced Chi-square  | B                   |
| Adj. R-square       | B                   |
| Fit status          | B                   |

Table A6. Sample P-5 rep.

| STATISTICS          | ANOVA               |
|---------------------|---------------------|
| Number of points    | 36                  |
| Degrees of freedom  | 30                  |
| Reduced Chi-square  | 1.786 × 10⁻⁶        |
| Adj. R-square       | 0.98493             |
| Fit status          | Succeeded (101)     |

| Number of points    | B                   |
| Degrees of freedom  | B                   |
| Reduced Chi-square  | B                   |
| Adj. R-square       | B                   |
| Fit status          | B                   |

Table A7. Sample P-10 rep.

| STATISTICS          | ANOVA               |
|---------------------|---------------------|
| Number of points    | 36                  |
| Degrees of freedom  | 28                  |
| Reduced Chi-square  | 4.269 × 10⁻⁶        |
| Adj. R-square       | 0.99762             |
| Fit status          | Succeeded (101)     |

| Number of points    | B                   |
| Degrees of freedom  | B                   |
| Reduced Chi-square  | B                   |
| Adj. R-square       | B                   |
| Fit status          | B                   |
Table A8. Sample P-15 rep.

| STATISTICS | ANOVA |
|------------|-------|
| **PM-15rep** |       |
| COD (R²) = 0.9947 |       |
| Area Intg. 0.7935 |       |
| Area Intg. 0.1175 |       |
| Wavenumber, cm⁻¹ |       |
| Number of baseline anchorn: 8 Connected by Fit Function: ExpGrow2 |       |
| Residual 80.0159 |       |
| Regression 6 0.0801 | 0.01335 | 5495.559 | 0 |
| Degrees of freedom 30 |       |
| Reduced Chi-square 2.429 × 10⁻⁶ |       |
| Adj. R-square 0.99376 |       |
| Fit status Succeed (100) |       |

Table A9. Sample P-20 rep.

| STATISTICS | ANOVA |
|------------|-------|
| **PM-20rep** |       |
| COD (R²) = 0.9882 |       |
| Area Intg. 1.229 |       |
| Area Intg. 0.124 |       |
| Wavenumber, cm⁻¹ |       |
| Number of baseline anchorn: 8 Connected by Fit Function: ExpGrow2 |       |
| Residual 80.0159 |       |
| Regression 8 0.08498 | 0.01062 | 7789.934 | 0 |
| Degrees of freedom 28 |       |
| Reduced Chi-square 1.3636 × 10⁻⁶ |       |
| Adj. R-square 0.99777 |       |
| Fit status Succeed (100) |       |

Table A10. Sample P-25 rep.

| STATISTICS | ANOVA |
|------------|-------|
| **PM-25rep** |       |
| COD (R²) = 0.9974 |       |
| Area Intg. 1.130 |       |
| Area Intg. 0.087 |       |
| Wavenumber, cm⁻¹ |       |
| Number of baseline anchorn: 8 Connected by Fit Function: ExpGrow2 |       |
| Residual 80.0159 |       |
| Regression 8 0.06424 | 0.00803 | 5404.575 | 0 |
| Degrees of freedom 28 |       |
| Reduced Chi-square 1.4858 × 10⁻⁶ |       |
| Adj. R-square 0.99673 |       |
| Fit status Succeed (100) |       |

References
1. Corsaro, C.; Neri, G.; Santoro, A.; Fazio, E. Acrylate and Methacrylate Polymers’ Applications: Second Life with Inexpensive and Sustainable Recycling Approaches. *Materials* 2022, 15, 282. [CrossRef] [PubMed]
2. dos Santos, J.; da Silva, G.S.; Velho, M.C.; Beck, R.C.R. Eudragit®: A Versatile Family of Polymers for Hot Melt Extrusion and 3D Printing Processes in Pharmaceutics. *Pharmaceutics* 2021, 13, 1424. [CrossRef] [PubMed]
3. Bhujiwal, S.V.; Mitra, B.; Jain, U.; Gong, Y.; Agrawal, A.; Karki, S.; Taylor, L.S.; Kumar, S.; Tony Zhou, Q. Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies. *Acta Pharm. Sin. B* 2021, 11, 2505–2536. [CrossRef] [PubMed]
4. Li, J.; Li, C.; Zhang, H.; Gao, X.; Wang, T.; Wang, Z.; Zheng, A. Preparation of Azithromycin Amorphous Solid Dispersion by Hot-Melt Extrusion: An Advantageous Technology with Taste Masking and Solubilization Effects. *Polymers* 2022, 14, 495. [CrossRef]
5. Han, J.; Li, L.; Su, M.; Heng, W.; Wei, Y.; Gao, Y.; Qian, S. Deaggregation and Crystallization Inhibition by Small Amount of Polymer Addition for a Co-Amorphous Curcumin-Magnolol System. *Pharmaceutics* 2021, 13, 1725. [CrossRef]
6. Thakral, S.; Thakral, N.K.; Majumdar, D.K. Eudragit®: A technology evaluation. *Expert Opin. Drug Deliv.* 2013, 10, 131–149. [CrossRef]
7. Lemanowicz, M.; Mielenzyk, A.; Walica, T.; Kotek, M.; Gierczycki, A. Application of Polymers as a Tool in Crystallization—A Review. *Polymers* 2021, 13, 2695. [CrossRef]
8. Kotiyan, P.N.; Vavia, P.R. Eudragits: Role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol. Eur. J. Pharm. Biopharm. 2001, 52, 173–180. [CrossRef]

9. Xie, T.; Gao, W.; Taylor, L.S. Impact of Eudragit EPO and hydroxypropyl methylcellulose on drug release rate, supersaturation, precipitation outcome and redissolution rate of indomethacin amorphous solid dispersions. Int. J. Pharm. 2017, 531, 313–323. [CrossRef]

10. Alhnan, M.A.; Basit, A.W. In-Process Crystallization of Acidic Drugs in Acrylic Microparticle Systems: Influence of Physical Factors and Drug–Polymer Interactions. J. Pharm. Sci. 2011, 100, 3284–3293. [CrossRef]

11. Kaur, G.; Grewal, J.; Jyoti, K.; Jain, U.K.; Chandra, R.; Madan, J. Oral controlled and sustained drug delivery systems: Concepts, advances, preclinical, and clinical status. In Drug Targeting and Stimuli Sensitive Drug Delivery Systems; Grumesescu, A.M., Ed.; William Andrew Publishing: Norwich, NY, USA, 2018; pp. 567–626. ISBN 9780128136898. [CrossRef]

12. Yus, C.; Gracia, R.; Larrea, A.; Andreu, V.; Irusta, S.; Sebastian, V.; Mendoza, G.; Arruebo, M. Targeted Release of Probiotics from Enteric Microparticulated Formulations. Polymers 2019, 11, 1668. [CrossRef] [PubMed]

13. Ivanova, N.; Trapani, A.; Franco, C.D.; Mandracchia, D.; Trapani, G.; Franchini, C.; Corbo, F.; Tripodo, G.; Kolev, I.; Stoyanov, G.; et al. In vitro and ex vivo studies on diltiazem hydrochloride-loaded microsponges in rectal gels for chronic anal fissures treatment. Int. J. Pharm. 2019, 557, 53–65. [CrossRef] [PubMed]

14. Kolev, I.; Ivanova, N.; Marinov, M.; Alexieva, G.; Strashilov, V. A QCM-based assay of drug content in Eudragit RS 100-based delivery systems. Talanta 2019, 202, 531–539. [CrossRef] [PubMed]

15. Borawake, P.D.; Kauslya, A.; Shinde, J.V.; Chavan, R.S. Microsphere as an Emerging Technique in Novel Drug Delivery System. J. Drug Deliv. Ther. 2021, 11, 171–182. [CrossRef] [PubMed]

16. Khattab, A.; Nattouf, A. Optimization of entrapment efficiency and release of clindamycin in microsphere based gel. Sci. Rep. 2021, 11, 23345. [CrossRef] [PubMed]

17. Chen, H.; Xu, H.; Wang, C.; Kang, H.; Haynes, C.L.; Mahanthappa, M.K.; Sun, C.C. Novel Quasi-Emulsion Solvent Diffusion-Based Spherical Cocristallization Strategy for Simultaneously Improving the Manufacturability and Dissolution of Indomethacin. Cryst. Growth Des. 2020, 20, 6752–6762. [CrossRef] [PubMed]

18. Mazzo, D.J.; Obetz, C.L.; Shuster, J. Diltiazem. In Analytical Profiles of Drug Substances and Excipients; Brittain, H.G., Ed.; Academic Press Inc.: Cambridge, MA, USA, 1994; pp. 53–98.

19. Swain, S.; Patra, C.N.; Bhanoji Rao, M.E. Pharmaceutical Drug Delivery Systems and Vehicles, 1st ed.; WPI Publishing: Worcester, MA, USA, 2016. [CrossRef]

20. Adnet, F.; Liquier, J.; Taillandier, E.; Singh, M.P.; Rao, K.E.; Lown, J.W. FTIR Study of Specific Binding Interactions Between DNA Minor Groove Binding Ligands and Polynucleotides. J. Biomol. Struct Dyn. 1992, 10, 565–575. [CrossRef] [PubMed]

21. Pudlas, M.; Kyeremateng, S.O.; Williams, L.A.M.; Kimber, J.A.; van Lishaut, H.; Kazarian, S.G.; Woehrle, G.H. Analyzing the impact of different excipients on drug release behavior in hot-melt extrusion formulations using FTIR spectroscopic imaging. Eur. J. Pharm. Sci. 2015, 67, 21–31. [CrossRef]

22. Socrates, G. Infrared and Raman Characteristic Group Frequencies: Tables and Charts, 3rd ed.; John Wiley & Sons Ltd.: Chichester, NH, USA, 2001; ISBN 9780470093078.

23. Stepanovs, D.; Jure, M.; Gosteva, M.; Popelis, J.; Kiselovs, G.; Mishnev, A. Crystal structures and physicochemical properties of diltiazem base and its acetylsalicylate, nicotinate and l-malate salts. CrystEngComm 2016, 18, 1235–1241. [CrossRef]

24. Türk, C.T.; Hasçiçek, Ç.; Gönül, N. Evaluation of drug-polymer interaction in polymeric microspheres containing diltiazem hydrochloride. J. Therm. Anal. Calorim. 2009, 95, 865–869. [CrossRef]

25. Sipos, P.; Szűcs, M.; Szabó, A.; Erős, I.; Szabó-Révész, P. An assessment of the interactions between diclofenac sodium and ammonio methacrylate copolymer using thermal analysis and Raman spectroscopy. J. Pharm. Biomed. Anal. 2008, 46, 288–294. [CrossRef] [PubMed]

26. Kulkarni, A.D.; Bari, D.B.; Surana, S.J.; Pardeshi, C.V. In vitro, ex vivo and in vivo performance of chitosan-based spray-dried nasal mucosubmicrospheres of diltiazem hydrochloride. J. Drug Deliv. Sci. Technol. 2016, 31, 108–117. [CrossRef]

27. Emara, L.; Abdelfattah, F.; Taha, F. Hot melt extrusion method for preparation of ibuprofen/sucroester WE15 solid dispersions: Evaluation and stability assessment. Journal of Applied Pharmaceutical Science. J. Appl. Pharm. Sci. 2017, 7, 156–167.

28. Liu, X.; Lu, X.; Su, Y.; Kun, E.; Zhang, F. Clay-Polymer Nanocomposites Prepared by Reactive Melt Extrusion for Sustained Drug Release. Pharmaceutics 2020, 12, 51. [CrossRef]

29. Kulkarni, R.V.; Mangond, B.S.; Mutalik, S.; Sa, B. Interpenetrating polymer network microcapsules of gellan gum and egg albumin entrapped with diltiazem–resin complex for controlled release application. Carbohydr. Polym. 2011, 83, 1001–1007. [CrossRef]